

In another aspect, there is provided a pharmaceutical composition comprising, as active principle, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

5 | In another ~~aspect~~embodiment, there is provided the use of a pharmaceutical composition as defined above in the manufacture of a medicament for the prevention or treatment of mental health diseases or disorders relating to orexinergic dysfunctions.


In another aspect, there is provided a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, for use as a medicament.

10 | In another aspect, there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of diseases or disorders selected from sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.

In this patent application, a dotted line shows the point of attachment of the radical drawn.

15 | For example, the radical drawn below

M.



or a pharmaceutically acceptable salt thereof.

5

9. A compound according to claim 1 which is

[(S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methyl-pyrrolidin-1-yl]-(5-methoxy-2-[1,2,3]triazol-2-yl-phenyl)-methanone;

or a pharmaceutically acceptable salt thereof.

10

10. A pharmaceutical composition comprising, as active principle, one or more compounds according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

15

~~11. Use of a pharmaceutical composition according to claim 10 in the manufacture of a medicament for the prevention or treatment of mental health diseases or disorders relating to orexinergic dysfunctions.~~

1211. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use as a medicament.

5 | ~~13~~12. Use of a compound as defined in according to any one of claims 1 to 9, or of a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of diseases or disorders relating to orexinergic dysfunctions, selected from sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, ~~and~~ or appetite disorders.

10 | 13. Use of a compound as defined in any one of claims 1 to 9, or of a pharmaceutically acceptable salt thereof, according to claim 12, wherein said diseases or disorders relating to orexinergic dysfunctions are selected from sleep disorders selected from insomnias; or anxiety disorders selected from post-traumatic stress disorders, obsessive compulsive disorders, panic attacks, phobic anxieties, or avoidance.